文献速递产科生殖医学

玻璃化冷冻囊胚移植后的围产期与母亲结局:CoNARTaS 北欧单胎研究

Perinatal and maternal outcome after vitrification of blastocysts: a Nordic study in singletons from the CoNARTaS group.
PubMed 文献 · Hum Reprod · 2019-01-01

基于北欧 CoNARTaS 登记库,纳入 2002-2015 年瑞典和丹麦单胎共 3650 例玻璃化囊胚移植、8123 例慢速冷冻卵裂期胚胎移植和 4469 例新鲜囊胚移植。玻璃化囊胚移植较慢速冷冻卵裂期胚胎移植早产风险升高(aOR 1.33 [1.09-1.62]),较新鲜囊胚移植巨大儿、大于胎龄儿、妊娠期高血压疾病和产后出血风险升高,小于胎龄儿和前置胎盘风险降低。

要点

  • 玻璃化囊胚移植较慢速冷冻卵裂期胚胎移植早产风险升高,aOR 1.33 [1.09-1.62]。
  • 玻璃化囊胚移植较新鲜囊胚移植巨大儿风险 aOR 1.77 [1.35-2.31],大于胎龄儿 aOR 1.48 [1.18-1.84]。
  • 玻璃化囊胚移植较新鲜囊胚移植妊娠期高血压疾病 aOR 1.47 [1.19-1.81],产后出血 aOR 1.68 [1.39-2.03]。

核心结论

  • 玻璃化囊胚移植较慢速冷冻卵裂期胚胎移植早产风险升高,aOR 1.33 [1.09-1.62]。
  • 玻璃化囊胚移植较新鲜囊胚移植巨大儿、大于胎龄儿、妊娠期高血压疾病和产后出血风险升高,小于胎龄儿和前置胎盘风险降低。
  • 作者认为从策略上改为玻璃化囊胚冷冻的结果令人放心,提示冷冻技术本身对围产期和母亲结局无重大影响,早产风险升高可能与延长胚胎培养而非玻璃化有关。

研究设计与样本

  • 基于登记库的队列研究,数据来自 CoNARTaS 组,基于瑞典、芬兰、丹麦和挪威的国家登记库,纳入 1984-2015 年公立和私立诊所 ART 治疗后出生的所有儿童。
  • 研究纳入 2002-2015 年瑞典和丹麦引入玻璃化冷冻后出生的单胎:玻璃化囊胚移植 3650 例、慢速冷冻卵裂期胚胎移植 8123 例、新鲜囊胚移植 4469 例。
  • 采用 logistic 多变量回归分析,调整国家与出生年份、母亲年龄、体重指数、产次、吸烟、父母教育水平、受精方式(IVF/ICSI)、单胚胎移植、孕囊数和胎儿性别。

主要发现

  • 玻璃化囊胚组较慢速冷冻卵裂期胚胎组早产(<37 周)风险升高,aOR 1.33 [1.09-1.62]。
  • 玻璃化囊胚组与慢速冷冻卵裂期胚胎组比较,低出生体重(<2500 g)、小于胎龄儿、巨大儿(≥4500 g)和大于胎龄儿均无显著差异。
  • 玻璃化囊胚组与慢速冷冻卵裂期胚胎组比较,妊娠期高血压疾病、前置胎盘、胎盘早剥和产后出血风险均无显著差异,但精确度有限。
  • 玻璃化囊胚组较新鲜囊胚组巨大儿(≥4500 g)aOR 1.77 [1.35-2.31]、大于胎龄儿 aOR 1.48 [1.18-1.84]、妊娠期高血压疾病 aOR 1.47 [1.19-1.81]、产后出血 aOR 1.68 [1.39-2.03] 风险升高。
  • 玻璃化囊胚组较新鲜囊胚组小于胎龄儿 aOR 0.58 [0.44-0.78] 和前置胎盘 aOR 0.35 [0.25-0.48] 风险降低。

关键数值与推荐

  • 早产(<37 周):玻璃化囊胚组 vs 慢速冷冻卵裂期胚胎组 aOR 1.33 [1.09-1.62]。
  • 巨大儿(≥4500 g):玻璃化囊胚组 vs 新鲜囊胚组 aOR 1.77 [1.35-2.31]。
  • 大于胎龄儿:玻璃化囊胚组 vs 新鲜囊胚组 aOR 1.48 [1.18-1.84]。
  • 妊娠期高血压疾病:玻璃化囊胚组 vs 新鲜囊胚组 aOR 1.47 [1.19-1.81]。
  • 产后出血:玻璃化囊胚组 vs 新鲜囊胚组 aOR 1.68 [1.39-2.03];小于胎龄儿 aOR 0.58 [0.44-0.78];前置胎盘 aOR 0.35 [0.25-0.48]。

临床怎么用

  • 作者认为从策略上改为玻璃化囊胚冷冻的结果令人放心,提示冷冻技术本身对围产期和母亲结局无重大影响。
  • 作者认为早产风险升高可能与延长胚胎培养而非玻璃化有关。

局限性

  • 由于瑞典和丹麦同时引入玻璃化和囊胚移植,本研究无法探讨玻璃化本身的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is transfer of vitrified blastocysts associated with higher perinatal and maternal risks compared with slow-frozen cleavage stage embryos and fresh blastocysts? SUMMARY ANSWER: Transfer of vitrified blastocysts is associated with a higher risk of preterm birth (PTB) when compared with slow-frozen cleavage stage embryos and with a higher risk of a large baby, hypertensive disorders in pregnancy (HDPs) and postpartum hemorrhage (PPH) but a lower risk of placenta previa when compared with fresh blastocysts. WHAT IS KNOWN ALREADY: Transfer of frozen-thawed embryos (FETs) plays a central role in modern fertility treatment, limiting the risk of ovarian hyperstimulation syndrome and multiple pregnancies. Following FET, several studies report a lower risk of PTB, low birth weight (LBW) and small for gestational age (SGA) yet a higher risk of fetal macrosomia and large for gestational age (LGA) compared with fresh embryos. In recent years, the introduction of new freezing techniques has increased treatment success. The slow-freeze technique combined with cleavage stage transfer has been replaced by vitrification and blastocyst transfer. Only few studies have compared perinatal and maternal outcomes after vitrification and slow-freeze and mainly in cleavage stage embryos, with most studies indicating similar outcomes in the two groups. Studies on perinatal and maternal outcomes following vitrified blastocysts are limited. STUDY DESIGN, SIZE, DURATION: This registry-based cohort study includes singletons born after frozen-thawed and fresh transfers following the introduction of vitrification in Sweden and Denmark, in 2002 and 2009, respectively. The study includes 3650 children born after transfer of vitrified blastocysts, 8123 children born after transfer of slow-frozen cleavage stage embryos and 4469 children born after transfer of fresh blastocysts during 2002-2015. Perinatal and maternal outcomes in singletons born after vitrified blastocyst transfer were compared with singletons born after slow-frozen cleavage stage transfer and singletons born after fresh blastocyst transfer. Main outcomes included PTB, LBW, macrosomia, HDP and placenta previa. PARTICIPANTS/MATERIALS, SETTING, METHODS: Data were obtained from the CoNARTaS (Committee of Nordic ART and Safety) group. Based on national registries in Sweden, Finland, Denmark and Norway, the CoNARTaS cohort includes all children born after ART treatment in public and private clinics 1984-2015. Outcomes were assessed with logistic multivariable regression analysis, adjusting for the country and year of birth, maternal age, body mass index, parity, smoking, parental educational level, fertilisation method (IVF/ICSI), single embryo transfer, number of gestational sacs and the child's sex. MAIN RESULTS AND THE ROLE OF CHANCE: A higher risk of PTB (<37 weeks) was noted in the vitrified blastocyst group compared with the slow-frozen cleavage stage group (adjusted odds ratio, aOR [95% CI], 1.33 [1.09-1.62]). No significant differences were observed for LBW (<2500 g), SGA, macrosomia (≥4500 g) and LGA when comparing the vitrified blastocyst with the slow-frozen cleavage stage group. For maternal outcomes, no significant difference was seen in the risk of HDP, placenta previa, placental abruption and PPH in the vitrified blastocyst versus the slow frozen cleavage stage group, although the precision was limited.When comparing vitrified and fresh blastocysts, we found higher risks of macrosomia (≥4500 g) aOR 1.77 [1.35-2.31] and LGA aOR 1.48 [1.18-1.84]. Further, the risks of HDP aOR 1.47 [1.19-1.81] and PPH aOR 1.68 [1.39-2.03] were higher in singletons born after vitrified compared with fresh blastocyst transfer while the risks of SGA aOR 0.58 [0.44-0.78] and placenta previa aOR 0.35 [0.25-0.48] were lower. LIMITATIONS, REASONS FOR CAUTION: Since vitrification was introduced simultaneously with blastocyst transfer in Sweden and Denmark, it was not possible to explore the effect of vitrification per se in this study. WIDER IMPLICATIONS OF THE FINDINGS: The results from the change of strategy to vitrification of blastocysts are reassuring, indicating that the freezing technique per se has no major influence on the perinatal and maternal outcomes. The higher risk of PTB may be related to the extended embryo culture rather than vitrification. STUDY FUNDING/COMPETING INTEREST(S): The study is part of the ReproUnion Collaborative study, co-financed by the European Union, Interreg V ÖKS. The study was also financed by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF agreement (LUA/ALF 70940), Hjalmar Svensson Research Foundation and NordForsk (project 71 450). There are no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: ISRCTN11780826.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Ginström Ernstad E, Spangmose AL, Opdahl S, et al. Perinatal and maternal outcome after vitrification of blastocysts: a Nordic study in singletons from the CoNARTaS group. Hum Reprod. 2019. PMID: 31687765. doi:10.1093/humrep/dez212

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。